Fosaprepitant-induced phlebitis: A focus on patients receiving doxorubicin/cyclophosphamide therapy

Supportive Care in Cancer

Volumn 22, Issue 5, 2014, Pages 1313-1317

  Leal, A D ^a   Kadakia, K C ^a   Looker, S ^a   Hilger, C ^a   Sorgatz, K ^a   Anderson, K ^a   Jacobson, A ^a   Grendahl, D ^a   Seisler, D ^a   Hobday, T ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adverse event; Chemotherapy induced nausea and vomiting; Fosaprepitant; Vein toxicity

Indexed keywords

APREPITANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOSAPREPITANT;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PATIENT PREFERENCE; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCAR FORMATION; SUPERFICIAL THROMBOPHLEBITIS; VEIN DISCOLORATION; VEIN DISEASE; VENOUS ENGORGEMENT; VENOUS HARDENING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MORPHOLINES; NAUSEA; PHLEBITIS; RETROSPECTIVE STUDIES; VOMITING;

EID: 84897529620     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2089-8     Document Type: Article

References (12)

1. Rogers MP (2010) Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Clin J Oncol Nurs 14(4):5
2. Hesketh PJ (2011) Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer 19
3. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104(7):1548-1555. doi: 10.1002/cncr.21343 (Pubitemid 41356171)
4. Herrington J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112
5. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A,Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423-431. doi: 10.1007/s00520-009-0680-9
6. Basch E (2011) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. J Clin Oncol 29(31)
7. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 29(11):1495-1501. doi: 10.1200/JCO.2010.31.7859
8. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47(7):834-840. doi: 10.1177/0091270007301800
9. EMEND (fosaprepitant dimeglumine) for Injection [package insert]. vol 2008. Merck & Co., Inc., Whitehouse Station, NJ
10. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadatadriven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377-381. doi: 10.1016/j.jbi.2008.08.010
11. Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2012) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. doi: 10.1093/annonc/mds541
12. Fujii T, Nishimura N, Kanai H, Ishimaru H, Kawano J, Takahashi O, Yamauchi H, Yamauchi T Impact of fosaprepitant use on dermal and vascular adverse events in anthracycline-based regimens administered through peripheral lines. In: 2013 ASCO Annual Meeting, Chicago, IL, 2013.